ECSP066959A - MACROCICLICAL COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION - Google Patents

MACROCICLICAL COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION

Info

Publication number
ECSP066959A
ECSP066959A EC2006006959A ECSP066959A ECSP066959A EC SP066959 A ECSP066959 A EC SP066959A EC 2006006959 A EC2006006959 A EC 2006006959A EC SP066959 A ECSP066959 A EC SP066959A EC SP066959 A ECSP066959 A EC SP066959A
Authority
EC
Ecuador
Prior art keywords
compounds
methods
macrociclical
inhibitors
viral replication
Prior art date
Application number
EC2006006959A
Other languages
Spanish (es)
Inventor
Lawrence M Blatt
Steven Mak Wenglowsky
Steven Wade Andrews
Yutong Jiang
April Layne Kennedy
Kevin Ronald Condroski
John Anthony Josey
Peter John Stengel
Machender R Madduru
George Andrew Doherty
Benjamin T Woodard
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of ECSP066959A publication Critical patent/ECSP066959A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En diversas realizaciones se proveen compuestos de las Fórmulas generales I-XIX, así como composiciones, entre las que se incluyen composiciones farmacéuticas, que comprenden un compuesto de la invención. Las realizaciones proveen además métodos de tratamiento, que incluyen métodos de tratamiento de infecciones flavivirales, que incluyen la infección por el virus de hepatitis C y métodos de tratar la fibrosis hepática. Los métodos consisten en general en la administración a un individuo que lo necesita, una cantidad eficaz de un compuesto o composición de la invención.In various embodiments, compounds of General Formulas I-XIX are provided, as well as compositions, including pharmaceutical compositions, which comprise a compound of the invention. The embodiments further provide treatment methods, which include methods of treating flaviviral infections, which include hepatitis C virus infection and methods of treating liver fibrosis. The methods generally consist of administering to an individual in need, an effective amount of a compound or composition of the invention.

EC2006006959A 2004-03-30 2006-10-27 MACROCICLICAL COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION ECSP066959A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55816104P 2004-03-30 2004-03-30
US56241804P 2004-04-14 2004-04-14
US61238104P 2004-09-22 2004-09-22
US61246004P 2004-09-22 2004-09-22

Publications (1)

Publication Number Publication Date
ECSP066959A true ECSP066959A (en) 2006-12-20

Family

ID=35005653

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006959A ECSP066959A (en) 2004-03-30 2006-10-27 MACROCICLICAL COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION

Country Status (16)

Country Link
EP (1) EP1749007A2 (en)
JP (1) JP4950026B2 (en)
AP (1) AP2006003763A0 (en)
AR (1) AR050321A1 (en)
AU (1) AU2005228894B9 (en)
BR (1) BRPI0509467A (en)
CA (1) CA2560897C (en)
CU (1) CU23787B7 (en)
EA (1) EA012389B1 (en)
EC (1) ECSP066959A (en)
GE (1) GEP20104926B (en)
IL (1) IL177917A0 (en)
MA (1) MA28548B1 (en)
NO (1) NO20064933L (en)
NZ (1) NZ549697A (en)
WO (1) WO2005095403A2 (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
JP5007226B2 (en) 2004-07-15 2012-08-22 エーエムアール テクノロジー インコーポレイテッド Aryl and heteroaryl substituted tetrahydroisoquinolines and their use to block reuptake of norepinephrine, dopamine, and serotonin
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1863833B1 (en) * 2005-03-08 2013-09-18 Boehringer Ingelheim International GmbH Process for preparing macrocyclic compounds
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
EP2305697A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
PL1919898T3 (en) * 2005-07-29 2011-06-30 Tibotec Pharm Ltd Macrocyclic inhibitors of hepatitis c virus
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2634743C (en) 2005-12-23 2014-07-29 Zealand Pharma A/S Modified lysine-mimetic compounds
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EA017448B1 (en) 2006-07-13 2012-12-28 Ачиллион Фармасьютикалз, Инк. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2357494T3 (en) * 2006-11-16 2011-04-27 Bristol-Myers Squibb Company MACROCYCLIC PEPTIDES AS INHIBITORS OF HEPATITIS C.
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) * 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2468724B1 (en) 2006-12-21 2015-11-18 Zealand Pharma A/S Synthesis of pyrrolidine compounds
KR20090101372A (en) * 2007-01-08 2009-09-25 페노믹스 코포레이션 Macrocyclic hepatitis c protease inhibitors
WO2008096002A1 (en) * 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates
US8435984B2 (en) 2007-02-26 2013-05-07 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
NZ581606A (en) * 2007-05-03 2012-06-29 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
WO2009005690A2 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
MX2009013827A (en) * 2007-06-29 2010-03-01 Gilead Sciences Inc Antiviral compounds.
AP2009005073A0 (en) 2007-06-29 2009-12-31 Gilead Sciences Inc Antiviral compounds
SE531698C2 (en) 2007-07-12 2009-07-07 Respiratorius Ab New bronchodilating a, b unsaturated amides
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CA2710144A1 (en) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
NZ586231A (en) 2007-12-21 2012-12-21 Avila Therapeutics Inc HCV protease inhibitors comprising a functionalised proline derivative
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
CN101910177B (en) * 2007-12-24 2013-08-28 泰博特克药品公司 Macrocyclic indoles as hepatitis C virus inhibitors
MX2010010660A (en) * 2008-04-11 2010-10-25 Hoffmann La Roche New ruthenium complexes as catalysts for metathesis reactions.
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5529120B2 (en) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Hepatitis C virus inhibitor
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
BRPI0916609A2 (en) * 2008-08-07 2015-08-04 Hoffmann La Roche Process for the preparation of a macrocycle
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
WO2010033443A1 (en) 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2364309T3 (en) 2008-12-10 2015-03-31 Achillion Pharmaceuticals Inc New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
EP3222628A1 (en) 2008-12-23 2017-09-27 Gilead Pharmasset LLC Nucleoside phosphoramidates
DK2401272T3 (en) 2009-02-27 2017-02-27 Janssen Pharmaceuticals Inc AMORF SALT OF A MACROCYCLIC INHIBITOR OF HCV
CA2758072A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
CN102458123A (en) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
KR101830447B1 (en) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-([1,2,4]TRIAZOLO[1,5-α]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
JP5739415B2 (en) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー (S) -7-([1,2,4] triazolo [1,5-a] pyridin-6-yl) -4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydroisoquinoline Crystal forms and uses thereof
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
PL2451438T3 (en) 2009-07-07 2014-07-31 Boehringer Ingelheim Int Pharmaceutical composition for a hepatitis c viral protease inhibitor
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
MX2012003171A (en) * 2009-09-28 2012-04-11 Hoffmann La Roche Novel macrocyclic inhibitors of hepatitis c virus replication.
CN102596201A (en) 2009-10-30 2012-07-18 贝林格尔.英格海姆国际有限公司 Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
BR112012018529A2 (en) 2010-01-25 2016-08-09 Enanta Pharm Inc hepatitis c virus inhibitors, their pharmaceutical composition and their use, and method for inhibiting replication of an rna-containing virus
PT3290428T (en) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
UY33312A (en) 2010-03-31 2011-10-31 Pharmasset Inc PURINE NUCLEOSIDE PHOSPHORAMIDATE
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
SG10202010119TA (en) 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc Macrocyclic hepatitis c serine protease inhibitors
TW201309690A (en) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013185284A1 (en) 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
BR112015007879A2 (en) 2012-10-19 2017-07-04 Bristol Myers Squibb Co hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP6342922B2 (en) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Hepatitis C virus inhibitor
JP2016515139A (en) 2013-03-14 2016-05-26 アキリオン ファーマシューティカルズ，インコーポレーテッド A new method for producing buckwheatprevir
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
BR112015023351A2 (en) 2013-03-15 2017-07-18 Achillion Pharmaceuticals Inc crystalline form of sovaprevir, pharmaceutical composition, and method for treating a disorder
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US11324799B2 (en) 2017-05-05 2022-05-10 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (en) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd INHIBITING PEPTIDES OF HEPATITIS C, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, THE USE OF THE SAME TO PREPARE A PHARMACEUTICAL COMPOSITION, THE USE OF AN INTERMEDIATE PRODUCT FOR THE PREPARATION OF THESE PEPTIDES AND A PROCEDURE FOR THE PREPARATION OF ANOGRAPH .
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
AU2002248147B2 (en) * 2000-11-20 2006-04-06 Bristol-Myers Squibb Company Hepatitis C tripeptide inhibitors
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
ES2350201T3 (en) * 2002-05-20 2011-01-20 Bristol-Myers Squibb Company HETEROCYCLIC SULPHAMIDES AS INHIBITORS OF HEPATITIS C VIRUS.
CA2540858C (en) * 2003-10-14 2009-12-08 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7608590B2 (en) * 2004-01-30 2009-10-27 Medivir Ab HCV NS-3 serine protease inhibitors

Also Published As

Publication number Publication date
NO20064933L (en) 2006-12-15
GEP20104926B (en) 2010-03-25
CU23787B7 (en) 2012-03-15
AP2006003763A0 (en) 2006-10-31
AU2005228894B2 (en) 2011-08-25
JP2007531749A (en) 2007-11-08
WO2005095403A2 (en) 2005-10-13
AR050321A1 (en) 2006-10-18
EA200601467A1 (en) 2007-06-29
CA2560897C (en) 2012-06-12
WO2005095403A3 (en) 2005-12-01
EP1749007A2 (en) 2007-02-07
IL177917A0 (en) 2006-12-31
EA012389B1 (en) 2009-10-30
MA28548B1 (en) 2007-04-03
BRPI0509467A (en) 2007-09-11
CU20090209A7 (en) 2011-04-26
CA2560897A1 (en) 2005-10-13
JP4950026B2 (en) 2012-06-13
AU2005228894A1 (en) 2005-10-13
NZ549697A (en) 2009-12-24
AU2005228894B9 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
ECSP066959A (en) MACROCICLICAL COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
CU20090112A6 (en) MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
AR055095A1 (en) NEW MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
ECSP066570A (en) MACROCYCLIC AND ACILSULPHONAMID CARBOXYLIC ACIDS AS HCV REPLICATION INHIBITORS
NI200900205A (en) NEW INHIBITOR PEPTIDES OF THE REPLICATION OF THE HEPATITIS C VIRUS.
ECSP099780A (en) NEW MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
CO6321290A2 (en) NEW MACROCICLIC INHIBITORS BASED ON PIRROLIDINYL OF THE VIRUS REPLICATION OF HEPATITIS C
UY29266A1 (en) PIRIDAZINONA COMPOUNDS
UY29868A1 (en) NUCLEOCIDOS 4 MODIFIED AS ANTIVIRAL AGENTS
WO2007047146A3 (en) Inhibitors of viral replication
ECSP077412A (en) TETRACYCLIC INDOL DERIVATIVES AS ANTI-AGENT AGENTS
BRPI0514176A (en) hcv replication inhibitors
EA200800178A1 (en) HEPATITIS C VIRUS INHIBITORS (HCV)
BRPI0418251C1 (en) phosphonates, monophosphonamidates, bisphosphonamidates, and pharmaceutical composition comprising them
BRPI0517463A (en) hepatitis c virus protease inhibitors, compositions and treatments using the same
SV2005001920A (en) "NUCLEOSID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS"
AR030591A1 (en) PEPTIDOMIMETIC PROTEASA INHIBITORS
EA200700718A1 (en) COMBINED ANTI-VIRAL COMPOSITIONS CONTAINING KASTANOSPERMIN AND METHODS OF THEIR APPLICATION
SV2005001919A (en) NUCLEOSID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS
CU23602A3 (en) MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
CU20090182A7 (en) NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
TW200611905A (en) Macrocyclic compounds as inhibitors of viral replication
CU20090188A7 (en) NEW INHIBITING PEPTIDES OF HEPATITIS C VIRUS REPLICATION
UA95455C2 (en) Macrocyclic inhibitors of hepatitis c virus replication